True or False: NLRP3 inflammasome activation in neutrophils triggers PAD release, increasing citrullination of intracellular proteins and contributing to rheumatoid arthritis pathogenesis. See if you got it right in this week's RheumIQ quiz at https://t.co/DX0qT1iNF2 https://t.co/rVuQM3aeI2

• RheumIQ Weekly Quiz | RheumNow

“Common sense in matters medical is rare, and is usually in inverse ratio to the degree of education.” – Sir William Osler

Which of the following is NOT a complication of Gout?

Review of Ruxolitinib in 7 pts w/ refractory systemic JIA complicated by macrophage activation (MAS) (ages 1.6-11 yrs; 3M: 4F). 5 achieved complete remission; 2 partial remission. 2 relapsed w/ GC tapering (remission after adding canakinumab). No deaths https://t.co/j4Cm3UYB9c https://t.co/pKoDwpSKII

• Frontiers | Case Report: Ruxolitinib for systemic juvenile idiopathic arthritis…

RepurpSS-II: Hydroxychloroquine plus Leflunomide in Sjögren's A small pilot, phase 2b trial has shown that the combination of leflunomide and hydroxychloroquine (LEF+HCQ) was effective and safe in treating patients with active Sjögren's disease. https://t.co/eeyhso0WJ6 https://t.co/ZGWOOtf92E

• RepurpSS-II: Hydroxychloroquine plus Leflunomide in Sjögren's | RheumNow

True or False: After successfully treating herpes zoster, it is considered safe to restart anti-TNF therapy without a significant risk of recurrence. See if you got it right in this week's RheumIQ quiz at https://t.co/DX0qT1iNF2 https://t.co/pGggdVPhmh

• RheumIQ Weekly Quiz | RheumNow

Cross-sectional study of 339 IBD pts (64% women, median 42yrs (32–53) found osteopenia by BMD in 34%, OP in 12%. Predictors not identified by multivariable analysis. Rheum eval led to OP Rx in 7% & vitamin D in 45% https://t.co/a9RSo9PxHS https://t.co/nIOR9AUjQs

• Screening for osteoporosis in patients with inflammatory bowel diseases: a cros…

Retrospective Intl SSc study of MD & PT telangiectasia counts (TC) (0, 1–6, 7–15 or > 15) of face, forearms & hands. High TC correlated w/ PAH (AUC 0.824–0.875) & digital ulcers. Moderate agreement betw MD & Pt for face & forearms TC (kappa 0.648 & 0.605, p< 0.001) https://t.co/k7tVeJFeCi

In the cross-sectional study of US SLE patients, what was the most common drug class driving polypharmacy beyond SLE medications? Test your knowledge in this week's RheumIQ quiz at https://t.co/DX0qT1iNF2 https://t.co/ox4rGp04WH

• RheumIQ Weekly Quiz | RheumNow

EGPA https://t.co/zlquehIZQ6

• https://x.com/aabdogafar/status/2060010189059670338/photo/1

FDA has approved that guselkumab (Tremfya) for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA) https://t.co/KwcECQpSz1 https://t.co/pSoK930FAX

• FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor pr…

LRA Awards for Immune Resetting Therapies in Lupus LRA, the world’s largest private funder of lupus research, in collaboration with Genentech, a member of the Roche Group, announced the inaugural recipients of the Lupus Research Alliance-Genentech Award on Immune Resetting https://t.co/eDAq17lhM0

Veterans Administration study of 301 #RA pts Rx w/ immune checkpoint inhibitor (ICI) for cancer shows all cause mortality in ICI Rx Cancer pts was no worse when RA pts took ICIs (1.09; 0.94–1.25). Cause of death similar; Infx were rare (<1.0%) https://t.co/3ZYujU5nyE https://t.co/MCDcdWHcVx

• Mortality in US Veterans With Rheumatoid Arthritis Treated With Immune Checkpoi…